Kura Oncology (KURA) Projected to Post Earnings on Thursday

Kura Oncology (NASDAQ:KURA - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 1st. Analysts expect Kura Oncology to post earnings of ($0.56) per share and revenue of $39.08 million for the quarter.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kura Oncology Stock Performance

KURA stock traded down $0.04 during midday trading on Tuesday, reaching $6.47. The stock had a trading volume of 110,967 shares, compared to its average volume of 1,144,172. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a fifty day simple moving average of $6.85 and a two-hundred day simple moving average of $9.85. The stock has a market cap of $522.63 million, a PE ratio of -2.74 and a beta of 0.83. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $23.48.

Analysts Set New Price Targets

KURA has been the subject of several recent research reports. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. UBS Group cut their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Scotiabank cut their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $25.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.